Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002429 · ClinicalTrials.gov registry record · Phase 3
Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT00002429 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 500 participants.
The verdict
NCT00002429, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
This study tests a new form of didanosine, ddI EC, a coated pill that passes through the stomach before dissolving. The purpose of this study is to compare the effectiveness of an anti-HIV drug combination that includes ddI EC versus another anti-HIV drug combination.
Interventions
- DRUG Stavudine
- DRUG Didanosine
- DRUG Nelfinavir mesylate
- DRUG Lamivudine/Zidovudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 1999-07 |
| Est. Completion | 2001-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002429
The ClinicalTrials.gov registry entry for NCT00002429 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Stavudine is the first listed.
NCT00002429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002429 about?
NCT00002429 is a clinical study titled "Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen". This study tests a new form of didanosine, ddI EC, a coated pill that passes through the stomach before dissolving. The purpose of this study is to compare the effectiveness of an anti-HIV drug combination that includes ddI EC versus another anti-HIV drug combination.
What is the current status of trial NCT00002429?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 1999-07. Estimated completion is 2001-01.
What interventions are being tested in trial NCT00002429?
The interventions under investigation include: Stavudine (DRUG), Didanosine (DRUG), Nelfinavir mesylate (DRUG), Lamivudine/Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00002429?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.